imatinib mesylate has been researched along with Aggressive Natural Killer Cell Leukemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bain, BJ; Barreira, R; Fernandes, F; Ramalho, R; Silveira, M | 1 |
| Cuzzola, M; Dattola, A; Fedele, R; Iacopino, P; Irrera, G; Martino, M; Messina, G | 1 |
| Loughran, TP; Yang, J | 1 |
3 other study(ies) available for imatinib mesylate and Aggressive Natural Killer Cell Leukemia
| Article | Year |
|---|---|
Large granular lymphocytosis induced by dasatinib.
Topics: Aged; Antineoplastic Agents; Cell Nucleus; Cytoplasmic Granules; Dasatinib; Drug Substitution; Female; Humans; Imatinib Mesylate; Immunophenotyping; Killer Cells, Natural; Leukemia, Large Granular Lymphocytic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes | 2021 |
Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease.
Topics: Benzamides; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Large Granular Lymphocytic; Piperazines; Pyrimidines; Time Factors; Treatment Outcome | 2011 |
Potential clinical application of imatinib mesylate in patients with leukemic large granular lymphocytes.
Topics: Benzamides; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Large Granular Lymphocytic; Piperazines; Pyrimidines | 2011 |